Evidence map›Paper›PMID 39778705›Full record

ArticleBrain : a journal of neurology2025

Human longevity and Alzheimer's disease variants act via microglia and oligodendrocyte gene networks.

Andrew C Graham, Eftychia Bellou, Janet C Harwood, Umran Yaman, Meral Celikag, Naciye Magusali, Naiomi Rambarack, Juan A Botia, Carlo Sala Frigerio, John Hardy and 2 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Genetic drivers of progression in Alzheimer's disease are distinct from disease risk.medRxiv : the preprint server for health sciences · 2025
    Article
  8. Article
  9. Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrew C GrahamUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0000-0002-7646-8705
Eftychia BellouUK Dementia Research Institute at Cardiff University, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK.ORCID 0000-0002-0971-5614
Janet C HarwoodDivision of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK.ORCID 0000-0002-3225-0069
Umran YamanUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0000-0003-4469-8407
Meral CelikagUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0009-0009-4733-3789
Naciye MagusaliUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0000-0003-1512-5474
Naiomi RambarackUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0009-0003-9760-6702
Juan A BotiaCommunications Engineering and Information Department, University of Murcia, 30100, Murcia, Spain.ORCID 0000-0002-6992-598X
Carlo Sala FrigerioUK Dementia Research Institute at University College London, London WC1E 6BT, UK.
John HardyUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0000-0002-3122-0423
Valentina Escott-PriceUK Dementia Research Institute at Cardiff University, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK.ORCID 0000-0003-1784-5483
Dervis A SalihUK Dementia Research Institute at University College London, London WC1E 6BT, UK.ORCID 0000-0001-7651-8998

Funding

Dolby FoundationMedical Research CouncilNational Institute for Health Research University College London Hospitals Biomedical Research CentreUK Dementia Research Institute DRI-1009
6 · The paper itself

Abstract

Ageing underlies functional decline of the brain and is the primary risk factor for several neurodegenerative conditions, including Alzheimer's disease (AD). However, the molecular mechanisms that cause functional decline of the brain during ageing, and how these contribute to AD pathogenesis, are not well understood. The objective of this study was to identify biological processes that are altered during ageing in the hippocampus and that modify Ad risk and lifespan, and then to identify putative gene drivers of these programmes. We integrated common human genetic variation associated with human lifespan or Ad from genome-wide association studies with co-expression transcriptome networks altered with age in the mouse and human hippocampus. Our work confirmed that genetic variation associated with Ad was enriched in gene networks expressed by microglia responding to ageing and revealed that they were also enriched in an oligodendrocytic gene network. Compellingly, longevity-associated genetic variation was enriched in a gene network expressed by homeostatic microglia whose expression declined with age. The genes driving this enrichment include CASP8 and STAT3, highlighting a potential role for these longevity-associated genes in the homeostatic functions of innate immune cells, and these genes might drive 'inflammageing'. Thus, we observed that gene variants contributing to ageing and AD balance different aspects of microglial and oligodendrocytic function. Furthermore, we also highlight putative Ad risk genes, such as LAPTM5, ITGAM and LILRB4, whose association with Ad falls below genome-wide significance but show strong co-expression with known Ad risk genes in these networks. Indeed, five of the putative risk genes highlighted by our analysis, ANKH, GRN, PLEKHA1, SNX1 and UNC5CL, have subsequently been identified as genome-wide significant risk genes in a subsequent genome-wide association study with larger sample size, validating our analysis. This work identifies new genes that influence ageing and AD pathogenesis, and highlights the importance of microglia and oligodendrocytes in the resilience of the brain against ageing and AD pathogenesis. Our findings have implications for developing markers indicating the physiological age of the brain and new targets for therapeutic intervention.

Indexed as

Alzheimer DiseaseGene Regulatory NetworksLongevityMicrogliaOligodendrogliaAgedAged, 80 and overAgingAnimalsFemaleGenetic VariationGenome-Wide Association StudyHippocampusHumansMaleMiceageingAlzheimer’s diseasehomeostasismicrogliamyelinoligodendrocytes

Identifiers

PMID39778705
PMCPMC11884759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.